Allogene spotlights their off-the-shelf CAR-T contender ‘501 with a snapshot on CRs and no GVHD
Allogene execs are out to revolutionize a field they played a major role in pioneering. And they will arrive — virtually — at ASCO with some solid evidence that they are on the right track.
The drug in the spotlight today is ALLO-501, which researchers are putting through their paces in a Phase I trial for relapsed/refractory non-Hodgkin lymphoma, in combination with their other in-house drug ALLO-647 to direction lymphodepletion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.